Journal article · 2025 · Open access

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Luciano J. Costa, Nizar Jacques Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gastón Caeiro, Alain Kentos, Vânia Hungria, Donna Ellen Reece, Ting Niu and 32 more

New England Journal of Medicine, 394(8), 739–752 · Published 9 December 2025 · DOI 10.1056/nejmoa2514663

Open PDFView at the publisherCite this paper

In brief

“Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma” is a 2025 journal article by Luciano J. Costa and 43 co-authors, published in New England Journal of Medicine. OpenAlex counts 133 citations as of 16 November 2026, which puts it in the top 7% of works published in 2025 by citations. It is open access: the full text is free to read at University of Southern Denmark Research Portal (University of Southern Denmark).

Citations
133
Most cited in
2026 (131)
Field-weighted impact
81.59
References
35
Authors
44

Abstract

BACKGROUND: In a phase 1-2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Daratumumab, a monoclonal antibody targeting CD38 protein, has shown survival benefit in patients with multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned patients with one to three previous lines of therapy to receive combination therapy with teclistamab-daratumumab or daratumumab combined with dexamethasone plus the investigator's choice of pomalidomide (DPd) or bortezomib (DVd) - the DPd or DVd group. The primary end point was progression-free survival, as assessed by an independent review committee. RESULTS: ; 58.4% vs. 17.1%) (P<0.001 for all comparisons). Serious adverse events occurred in 70.7% of the patients in the teclistamab-daratumumab group and in 62.4% of those in the DPd or DVd group; death from adverse events occurred in 7.1% and 5.9%, respectively. CONCLUSIONS: In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., Reece, D. E., Niu, T., Mylin, A. K., Hansen, C. T., Teipel, R., Besemer, B., Dimopoulos, M. A., Zamagni, E., Yoshihara, S., . . . Mateos, M. (2025). Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 394(8), 739–752. https://doi.org/10.1056/nejmoa2514663

MLA 9

Costa, Luciano J., et al. “Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.” New England Journal of Medicine, vol. 394, no. 8, 2025, pp. 739–752. https://doi.org/10.1056/nejmoa2514663.

Chicago

Costa, Luciano J., Nizar Jacques Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, et al. 2025. “Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.” New England Journal of Medicine 394 (8): 739–752. https://doi.org/10.1056/nejmoa2514663.

Harvard

Costa, L. J. et al. (2025) ‘Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma’, New England Journal of Medicine, 394(8), pp. 739–752. doi:10.1056/nejmoa2514663.

IEEE

L. J. Costa et al., “Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma,” New England Journal of Medicine, vol. 394, no. 8, pp. 739–752, 2025, doi: 10.1056/nejmoa2514663.

BibTeX

@article{costa2025teclistamab,
  title     = {{Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma}},
  author    = {Costa, Luciano J. and Bahlis, Nizar Jacques and Perrot, Aurore and Nooka, Ajay K. and Lu, Jin and Pawlyn, Charlotte and Mina, Roberto and Caeiro, Gastón and Kentos, Alain and Hungria, Vânia and Reece, Donna Ellen and Niu, Ting and Mylin, Anne K. and Hansen, Charlotte Thim and Teipel, Raphael and Besemer, Britta and Dimopoulos, Meletios Athanasios and Zamagni, Elena and Yoshihara, Satoshi and Kım, Kihyun and Min, Chang‐Ki and Geerts, Paul A. F. and van Leeuwen-Segarceanu, Elena and Tyczyńska, Agata and Reguera, Juan Luis and Johansson, Magnus and Hansson, Markus and Turgut, Mehmet and Grey, Mark and Sidana, Surbhi and others},
  journal   = {New England Journal of Medicine},
  year      = {2025},
  volume    = {394},
  number    = {8},
  pages     = {739--752},
  doi       = {10.1056/nejmoa2514663},
  url       = {https://doi.org/10.1056/nejmoa2514663}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments

  • teclistamab
  • daratumumab
  • relapsed/refractory multiple myeloma
  • bispecific antibodies
  • CD38
  • progression-free survival
  • dexamethasone
  • pomalidomide

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., Reece, D. E., Niu, T., Mylin, A. K., Hansen, C. T., Teipel, R., Besemer, B., Dimopoulos, M. A., Zamagni, E., Yoshihara, S., . . . Mateos, M. (2025). Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 394(8), 739–752. https://doi.org/10.1056/nejmoa2514663

How many times has this paper been cited?

133 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at University of Southern Denmark Research Portal (University of Southern Denmark): sign in and open the PDF from this page.

Who wrote this paper?

Luciano J. Costa, Nizar Jacques Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gastón Caeiro, Alain Kentos, Vânia Hungria, Donna Ellen Reece, Ting Niu and 32 more.

What is the DOI of this paper?

10.1056/nejmoa2514663, permanently at https://doi.org/10.1056/nejmoa2514663. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.